Therapy of metastasis in canine osteosarcoma
1989
MacEwen, E.G. | Kurzman, I.D. | Smith, B.W. | Rosenthal, R.C.
Canine osteosarcoma is a spontaneous malignancy in dogs which is characterized by micrometastases to pulmonary and extrapulmonary tissues at the time of diagnosis. The standard tratment involves amputation of the affected leg, but the median survival time is 3-4 months with death due to pulmonary and extrapulmonary metastases. We have been conducting a randomized double-blind trial to evaluate liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (liposme/MTP-PE) as a treatment for metastases in dogs undergoing amputation for osteosarcoma. To date we have entered 27 dogs into the study. Dogs were treated with MTP-PE at a dose of 2 mg/m-2 I.V. starting 24 hours after amputation. Treatments were given twice weekly for 8 weeks. The liposomes were a mixture of phosphatidylserine and phosphatidylcholine at a 3:7 molar ratio. Thirteen dogs were treated with empty liposomes and 14 wer treated with liposome/MTP-PE. The median survival time for the dogs treated with empty liposomes was 77 days (range: 31-438 days) as compared to dogs treated with liposome/MPT-PE group for which the median survival was 222 days (range: 81-820+); p < 0.004. In the liposome/MTP-PE group there are 5 dogs alive and free of metastases at one year post surgery.
显示更多 [+] 显示较少 [-]